Cohance Lifesciences Ltd share price inched up 0.05% to Rs 425.2. The Company's net profit witnessed a sharp fall of 643.80% to Rs 45.19 crore, while revenue from operations dropped sharply 31.80% to Rs 422.26 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, easing 4.98%. It has improved by 0.66% over last one week and advanced by 11.72% in last one month while the market capitalization of Cohance Lifesciences Ltd has softened by 0.58% and 11.54% in the same period respectively. Profit before tax (PBT) of Cohance Lifesciences Ltd stood at Rs 42.87 crore in Q2 FY26, plunging by 168.31% year-on-year, and nosediving by 315.32% quarter-on-quarter. EBITDA came in at Rs 11 crore, tanking 111.33% YoY and tumbling by 111.03% sequentially. Total expenses dropped by 17.67% to Rs 470.64 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 158.68 crore, advancing by 14.19% YoY, while employee benefits expense was at Rs 132.96 crore, ticking higher by 3.08% YoY. For the TTM ended FY26, revenue from operations surged 148.11% to Rs 2608.5 crore, while net profit surged by 61.26% to Rs 484.24 crore, compared to previous TTM. EBITDA jumped by 45510% to Rs 727.85 crore, and PBT witnessed a strong rise of 58.41% to Rs 642.63 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 673.35 crore in FY26, as against Rs 384.77 crore in FY25. Cohance Lifesciences Ltd nosedived by 55.63% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.20% during the same period.
